ECC 4703
Alternative Names: ECC-4703Latest Information Update: 22 Sep 2026
At a glance
- Originator Eccogene
- Class Antihyperlipidaemics; Hepatoprotectants; Obesity therapies; Small molecules
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis; Obesity
- No development reported Dyslipidaemias
Most Recent Events
- 07 Aug 2026 Eccogene initiates a phase-I pharmacokinetics trial (In volunteers) in Australia (PO) (NCT07726368)
- 28 Jul 2026 Eccogene plans a phase-I pharmacokinetics trial (In volunteers) in Australia in July 2026 (PO) (NCT07726368),
- 28 May 2026 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in China (PO, Capsule)